These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35251981)

  • 1. Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review.
    Chi Y; Shang M; Xu L; Gong H; Tao R; Song L; Zhang B; Yin S; Cong B; Li H
    Front Oncol; 2022; 12():811919. PubMed ID: 35251981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
    Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M
    Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature.
    de Bernardi A; Bachelot T; Larrouquère L
    Front Oncol; 2023; 13():1210873. PubMed ID: 38269026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
    Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
    Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations.
    Tian H; Qu M; Zhang G; Yuan L; Shi Q; Wang Y; Yang Y; Zhang Y; Qi X
    Oncologist; 2023 Jul; 28(7):e534-e541. PubMed ID: 37120151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
    Front Oncol; 2021; 11():664429. PubMed ID: 33996589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review.
    Liu M; Zhou X
    Gland Surg; 2023 Feb; 12(2):317-323. PubMed ID: 36915810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
    Oberkampf F; Gutierrez M; Trabelsi Grati O; Le Rhun É; Trédan O; Turbiez I; Kadi A; Dubot C; Taillibert S; Vacher S; Bonneau C
    Neuro Oncol; 2023 Feb; 25(2):365-374. PubMed ID: 35868630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.
    Singh DD; Lee HJ; Yadav DK
    Front Pharmacol; 2022; 13():1089066. PubMed ID: 36578543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.
    Xu J; Chen J; Huang P; Zhou H; Wang X; Chen Z
    Transl Breast Cancer Res; 2023; 4():25. PubMed ID: 38751473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report.
    Chen Y; Liu C; Wen X; Wang C; He J
    Int J Womens Health; 2024; 16():1277-1283. PubMed ID: 39100110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
    Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
    Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis.
    Werter IM; Remmelzwaal S; Burchell GL; de Gruijl TD; Konings IR; van der Vliet HJ; Menke-van der Houven van Oordt CW
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.
    Wang N; Li L; Xiong Y; Chi J; Liu X; Zhong C; Wang F; Gu Y
    Front Oncol; 2021; 11():729212. PubMed ID: 34976791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
    Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
    Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.